Pharmaceutical intermediates
(LCZ696) Intermediates
3 pharmaceutical intermediates for (LCZ696). Indication: Hypertension; Essential hypertension; Heart failure.
About (LCZ696)
- Originator
- Novartis Pharmaceuticals Corp
- Indication
- Hypertension; Essential hypertension; Heart failure
- Approved Date
- 07/07/2015
- DS/DP
- 01/15/2025
Available intermediates
3 intermediates currently listed for (LCZ696). Request specifications, documentation or a quotation for any item below.
| Product Name | CAS No. | Molecular Formula | Physical Properties |
|---|---|---|---|
| AHU-377 (heMicalciuM salt) | 1369773-39-6 | / | / |
| (2R,4S)-5-([1,1'-biphenyl]-4-yl)-4-((tert-butoxycarbonyl)aMino)-2-Methylpentanoic acid | 1012341-50-2 | / | / |
| (R,E)-5-([1,1'-biphenyl]-4-yl)-4-((tert-butoxycarbonyl)aMino)-2-Methylpent-2-enoic acid | 1012341-48-8 | / | / |
Building toward (LCZ696)?
Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →